MedTrace Logo

Topical 2% Povidone-Iodine Gel in Verruca Vulgaris

NCT04253912 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-04-01

No results posted yet for this study

Summary

This is a multi-center, randomized, double-blind, placebo-controlled phase 2 study in subjects 8 years of age and older who present with verruca vulgaris (common warts) and desire treatment. Subjects may have up to a total of 6 common warts located on their trunk or extremities that will be treated with study medication and followed throughout the study protocol therapy. All warts will be treated two times per day (BID) for12 weeks. Approximately 90 subjects will be enrolled in this study.

Conditions

  • Warts

Interventions

DRUG

VBP-245

2% Povidone-Iodine Gel

DRUG

Placebo Gel (no Povidone-Iodine)

Placebo Gel (no Povidone-Iodine)

Sponsors & Collaborators

  • Veloce BioPharma LLC

    lead INDUSTRY

Principal Investigators

  • Samuel Barone, MD · Veloce BioPharma LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-12
Primary Completion
2021-01-05
Completion
2021-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04253912 on ClinicalTrials.gov